Ioannis Katafigiotis

Ioannis Katafigiotis

Auto-generated profile, based on publicly available information

Ioannis Katafigiotis

1st University Urology Clinic, Laiko Hospital, Athens

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
IKIoannis Katafigiotis
Ioannis Katafigiotis
SSStavros Sfoungaristos
Stavros Sfoungaristos
MDMordechai Duvdevani
Mordechai Duvdevani
PMPanagiotis Mitsos
Panagiotis Mitsos
EREleni Roumelioti
Eleni Roumelioti
CCConstantinos A. Constantinides
Constantinos A. Constantinides
Primary adenocarcinoma of the seminal vesicles (SV) are extremely rare and approximately only 60 cases have been reported in the literature. Due to the lack of specific symptoms the patients often present in an advanced stage of their disease. The only clinical examination that can indicate the presence of a neoplasm in the SVs is the digital rectal examination (DRE). Serum prostatic specific antigen (PSA) and prostate specific acid phosphatase (PAP) are usually normal in patients with primary adenocarcinoma of the SV and only CA-125 can be proved a useful blood biomarker contributing to the diagnosis and the follow up of the SV adenocarcinoma. Computed tomography (CT) and magnetic resonance imaging (MRI) and FDG-PET/CT have been used for the diagnosis and the staging of the SV adenocarcinoma. Various combinations of radical surgery, radiotherapy androgen deprivation therapy and chemotherapy have been proposed for the management of the disease but the prognosis is poor and the mean survival is two years after the diagnosis.

1 October 2013 in Parasitology International
Verified
Journal Article
Closed access
IKIoannis Katafigiotis
Ioannis Katafigiotis
EFEvangelos Fragkiadis
Evangelos Fragkiadis
CPChristos Pournaras
Christos Pournaras
ANAfrodite Nonni
Afrodite Nonni
KSKonstantinos G. Stravodimos
Konstantinos G. Stravodimos


2 August 2022 in Cancers
Verified
Journal Article
Open access
PDF file
VLVasiliki Lygirou
Vasiliki Lygirou
KFKonstantinos Fasoulakis
Konstantinos Fasoulakis
RSRafael Stroggilos
Rafael Stroggilos
Manousos MakridakisManousos Makridakis
Manousos Makridakis
ALAgnieszka Latosinska
Agnieszka Latosinska
JZJerome Zoidakis
Jerome Zoidakis
Prostate cancer (PCa) is the second most common cancer in men. Diagnosis and risk assessment are widely based on serum Prostate Specific Antigen (PSA) and biopsy, which might not represent the exact degree of PCa risk. Towards the discovery of biomarkers for better patient stratification, we performed proteomic analysis of Formalin Fixed Paraffin Embedded (FFPE) prostate tissue specimens using liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS). Comparative analysis of 86 PCa samples among grade groups 1–5 identified 301 significantly altered proteins. Additional analysis based on biochemical recurrence (BCR; BCR+ n = 14, BCR- n = 51) revealed 197 significantly altered proteins that indicate disease persistence. Filtering the overlapping proteins of these analyses, seven proteins (NPM1, UQCRH, HSPA9, MRPL3, VCAN, SERBP1, HSPE1) had increased expression in advanced grades and in BCR+/BCR- and may play a critical role in PCa aggressiveness. Notably, all seven proteins were significantly associated with progression in Prostate Cancer Transcriptome Atles (PCTA) and NPM1NPM1, UQCRH, and VCAN were further validated in The Cancer Genome Atlas (TCGA), where they were upregulated in BCR+/BCR-. UQCRH levels were also associated with poorer 5-year survival. Our study provides valuable insights into the key regulators of PCa progression and aggressiveness. The seven selected proteins could be used for the development of risk assessment tools.

25 May 2018 in Medical Oncology
Verified
Journal Article
Closed access
PDF file
ISIoannis Skarmoutsos
Ioannis Skarmoutsos
ASAthanasios Skarmoutsos
Athanasios Skarmoutsos
IKIoannis Katafigiotis
Ioannis Katafigiotis
ETElisavet Tataki
Elisavet Tataki
AGAthina Giagini
Athina Giagini
CCConstantinos Constantinides
Constantinos Constantinides

30 April 2012 in BMC Geriatrics
Verified
Journal Article
Open access
PDF file
STStavros I Tyritzis
Stavros I Tyritzis
IAIoannis Anastasiou
Ioannis Anastasiou
KSKonstantinos G Stravodimos
Konstantinos G Stravodimos
AAAristeides Alevizopoulos
Aristeides Alevizopoulos
AKAnastasios Kollias
Anastasios Kollias
CCConstantinos Constantinides
Constantinos Constantinides
Radical cystectomy (RC) is probably underused in elderly patients due to a potential increased postoperative complication risk, as reflected by their considerable comorbidities. Our objective was to estimate the overall complication rate and investigate a potential benefit to patients over the age of 75 subjected to RC in terms of disease-free survival.